Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
2024年4月17日 - 9:00PM
Bionano Genomics, Inc. (BNGO), a global leader in the
transformation of the cytogenetic workflow with OGM, today
announced that it has entered into an original equipment
manufacturing (OEM) partnership agreement with Diagens, an assisted
reproductive technology company based in China focused on the
application of AI in cytogenetics. Through the partnership, the
companies plan to commercialize the first ever cytogenetic workflow
using OGM plus AI chromosome karyotype analysis to detect
pathogenic SVs associated with recurrent pregnancy loss and other
significant genome variants that may impact a pregnancy or lead to
developmental issues in a newborn.
Diagens has received Class I registration and approval for
Bionano’s OGM reagents from China's NMPA and will register the
Saphyr™ instrument with NMPA for clinical use in reproductive
health.
“As a pioneer in AI chromosome karyotype analysis, we are very
happy to establish a partnership with Bionano and to jointly
explore the reproductive health market. Diagens offers cutting-edge
AI technology to help our customers to achieve a better overall
success rate of in vitro fertilization. Bionano’s platform can help
us achieve this goal as it can identify structural variations in a
more precise way than karyotyping alone, and on a much broader
scale. Additionally, we look forward to potentially expanding the
cooperation into more fields, like blood cancer in the future,”
stated Ning Song, PhD, chief executive officer of Diagens.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, said, “We recognize the importance of AI in solving
clinical bottlenecks and resolving other limitations, including the
need for analysis and interpretation of data by highly trained
individuals. We believe the transformative approach of combining
OGM and AI in a cytogenetic workflow will advance SV detection in
constitutional genetic disorder research that will have the
potential to aid China’s large population seeking support for
reproductive health, including genetic analysis of individuals
considering pregnancy, pre-implantation analysis of in vitro
fertilized embryos, and other prenatal and postnatal genome
analyses."
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research,
and nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. Through
its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides OGM-based
testing for certain laboratory developed tests. The Company also
offers an industry-leading, platform-agnostic software solution,
which integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionano.com,
www.bionanolaboratories.com or www.purigenbio.com.
Except as specifically noted otherwise, Bionano’s products are
for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “may,” “expect,” “plan,”
“potential,” “will” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the ability and
utility of combining AI analysis and OGM to detect pathogenic SVs
associated with recurrent pregnancy loss and other genome variants
that could impact a pregnancy or lead to developmental issues for
the newborn; and the ability and utility of combining OGM and AI in
a cytogenetic workflow to advance SV detection in constitutional
genetic disorder research and aid China’s population seeking
support for reproductive health, including genetic analysis of
people considering pregnancy, pre-implantation analysis of in vitro
fertilized embryos, and other prenatal and postnatal genome
analyses; the ability of our OEM partner to obtain the
registrations and approvals from the NMPA described in this press
release; and other statements which are not of historical fact.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and potential future
bank failures, supply chain disruptions, global pandemics,
inflation and the ongoing conflicts between Ukraine and Russian and
Israel and Hamas, on our business and the global economy; general
market conditions; the failure of the combined AI analysis and OGM
to detect pathogenic SVs associated with recurrent pregnancy loss
and other genome variants that could impact a pregnancy or lead to
developmental issues for the newborn; the failure of and the
ability and utility of combining OGM and AI in a cytogenetic
workflow to advance SV detection in constitutional genetic disorder
research and aid China’s population seeking support for
reproductive health, including genetic analysis of people
considering pregnancy, pre-implantation analysis of in vitro
fertilized embryos, and other prenatal and postnatal genome
analyses; the failure of our OEM partner to obtain the
registrations and approvals from the NMPA to commercialize the
solutions described in this press release; the failure of our OEM
partner to achieve market success in the commercialization of the
solutions described in this press release; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; changes in
our strategic and commercial plans or the strategic or commercial
plans of our OEM partner; our need and ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts, our ability to effectively manage our uses of cash, and
our ability to continue as a “going concern”; the ability of
institutions to obtain funding to support adoption or continued use
of our technologies and the solutions offered by our OEM partner;
and the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2023 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 4 2024 まで 5 2024
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 5 2023 まで 5 2024